SURVYR

NBTX

Nanobiotix S.A.
$26.59
+$2.45 (10.15%)Oct 21 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-40%+3%+47%+90%+133%Oct 2025Oct 2026Apr 202652w high $57.1452w low $14.78
NBTXSPY
Wall St. Highest PT $69.12 (+159.9%) Wall St. Avg PT $53.96 (+102.9%)
$15$35$54$74$93POC $22Hi $69Avg $54
Underwater Drawdown %Max DD -61.7%Current -51.7%
0.0%-61.7%
Relative Strength vs SPY-8.0% vs SPYUnderperforming
+129%0%-129%
1W
+$5.31 (24.95%)
1M
−$7.91 (22.93%)
3M
−$13.79 (34.15%)
6M
−$5.60 (17.41%)
YTD
+$3.47 (15.01%)
1Y
+$3.97 (17.55%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Analyst price targets
Current price$26.59
Average target$53.96
+$27.37 (+102.9%) upsideaverage target vs current price
CurrentAverageMedian
Low$29.55
Median$53.96
High$69.12
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-06-04 · Leerink Partners reiterated Outperform on NBTX
Reiterated
2026-05-01 · UBS reiterated Neutral on NBTX
Reiterated
2026-04-02 · Guggenheim reiterated Buy on NBTX
Reiterated
2026-02-06 · Guggenheim reiterated Buy on NBTX
Reiterated
2025-04-04 · Guggenheim reiterated Buy on NBTX
Initiated
2024-08-28 · Guggenheim started covering NBTX at Buy
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$1.4B
P/E (next 12 months, estimated)-158.8
52-week range$14.78 – $57.14
Revenue growth (latest quarter vs a year ago)-79.2%
Dividend yieldNo dividend
Average analyst price target$53.96 (+103%)

What they do

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for NBTX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

NBTX earningsNext report in 154 days
Next report
Tue Mar 30, 2027After the close
EPS consensus–
Revenue consensus$0
Last 4 quarters · EPS vs estimate
Apr 7, 2022-$0.20est -$1.06+81.2%Above estimates
Apr 7, 2022-$0.16est -$0.45+64.5%Above estimates
Apr 7, 2022-$0.16est -$0.59+73.0%Above estimates
Apr 7, 2022-$0.20est -$1.05+80.9%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 11:25:45 ET
22-0422-0422-0422-04-1.060.00
EstimateActual (beat)Actual (miss)

News & catalysts

More news
Voting Rights and Shares Capital of the Company
GlobeNewswire · Oct 20
Nanobiotix (ENXTPA:NANO) Could Be 59% Undervalued After Its CFO Change
Simply Wall St. · Oct 10
Nanobiotix Appoints Arnd Christ as CFO
MT Newswires · Oct 01
NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
GlobeNewswire · Oct 01
Can J&J’s Partnership Drive More Upside for Nanobiotix?
Insider Monkey · Sep 28
Rating changes
Reiterated
2026-06-04 · Leerink Partners reiterated Outperform on NBTX
Reiterated
2026-05-01 · UBS reiterated Neutral on NBTX
Reiterated
2026-04-02 · Guggenheim reiterated Buy on NBTX
Reiterated
2026-02-06 · Guggenheim reiterated Buy on NBTX
Reiterated
2025-04-04 · Guggenheim reiterated Buy on NBTX
Initiated
2024-08-28 · Guggenheim started covering NBTX at Buy

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-21 11:25:45 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026